Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2009

View Archived Issues

Aflunov vaccine immunogenic and well tolerated in children and adolescents

FDA approves Roche's test to screen source plasma for HIV, HBV and HCV

Phase I trial reveals promising activity of MGCD-265 in advanced malignancies

NMS-P-715 inhibits tumor growth by targeting the mitotic checkpoint

Astellas reports results from first half of 2009, ended September 30

Shionogi reports results from Q2 of 2009, ended September 30

AstraZeneca and Targacept collaborate on TC-5214 for major depressive disorder

Cosmo Technologies completes enrollment in phase III budesonide MMX trial

Cubist closes enrollment early in CONSERV-1 and CONSERV-2

Novavax reports promising results from pandemic influenza vaccine trial

FDA approves Novo Nordisk's Vagifem 10 mcg for atrophic vaginitis due to menopause

Peregrine completes enrollment in dose confirmation trial of Cotara in brain cancer

Via Pharmaceuticals completes patient visits in phase II VIA-2291 trial

Tripep receives approval to expand ChronVac-C study

API-101.10 protects against hyperoxia-induced retinopathy in vivo

Antithrombotic nanobody ALX-0681 safe and well tolerated in healthy volunteers

Safety of MLN-4924 in MM and NHL shown in preliminary data from phase I trial

CK2 inhibitors for the treatment of cancer in development at Cylene Pharmaceuticals

Auckland UniServices claims PI3K p110alpha inhibitors for cancer therapy

Novel prostanoid EP2 agonists disclosed by Ube for asthma therapy

Forest identifies novel SCD1 inhibitors for the treatment of obesity

German scientists describe novel ClpP inhibitors as antibacterial agents

Amira presents initial phase I data for AM-461

Chaperone Technologies and MerLion collaborate on antimicrobials

FDA approves Lilly's Zyprexa tablets for psychiatric disorders in adolescents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...